Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190)

Hong Kong · Delayed Price · Currency is HKD

19.08

-0.01 (-0.05%)

Jul 31, 2026, 4:08 PM HKT

-21.48% (1Y)

Market Cap	6.32B -20.2%
Revenue (ttm)	1.18B +35.1%
Net Income	271.94M +143.7%
EPS	0.84 +147.0%
Shares Out	331.39M
PE Ratio	22.70
Forward PE	15.70
Dividend	0.26 (1.34%)
Ex-Dividend Date	May 27, 2026

Volume	74,520
Open	19.09
Previous Close	19.09
Day's Range	18.82 - 19.12
52-Week Range	17.10 - 28.00
Beta	0.28
Analysts	Strong Buy
Price Target	31.22 (+63.63%)
Earnings Date	Aug 20, 2026

About HKG:2190

Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices in the People’s Republic of China and internationally. It offers a neurovascular product portfolio that covers a suite of products for various categories, including ischemic stroke, hemorrhagic stroke, intracranial stenosis, carotid artery, and intracranial access devices. The company’s peripheral-vascular interventional product portfolio includes stents, balloons, catheters, and filters, as well as cove... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2012

Employees 925

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2190

Full Company Profile

Financial Performance

In 2025, HKG:2190's revenue was 1.06 billion, an increase of 35.15% compared to the previous year's 782.48 million. Earnings were 244.37 million, an increase of 143.75%.

Financial numbers in CNY Financial Statements

Analyst Summary

According to 4 analysts, the average rating for 2190 stock is "Strong Buy." The 12-month stock price target is $31.22, which is an increase of 63.63% from the latest price.

Price Target

$31.22

(63.63% upside)

Analyst Consensus: Strong Buy

Stock Forecasts